will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might control clinical symptoms and hormone release in patients ...

These symptoms depends on where in your body the tumor has grown. Patients who have appendiceal neuroendocrine tumors may have symptoms of appendicitis, such as pain in abdomen. They could also be ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors. 177Lu-edotreotide shows potential to extend ...

Different cancers have different risk factors.­ Having one or more of these risk factors doesn't mean you will definitely get that cancer. There are 2 key groups of neuroendocrine cancer: ...

The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer Inc. are investing in innovative ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Neuroendocrine tumors (NETs) are rare ... NETs can be difficult to diagnosis as symptoms can mimic other diseases. Symptoms can include abdominal pain, flushing, diarrhea, heart palpitations ...